Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411184 | PMC |
| http://dx.doi.org/10.3389/fpls.2023.1257823 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study.
Dermatol Ther (Heidelb)
January 2025
Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy.
Introduction: Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets.
Objectives: This study aimed to investigate changes in circulating miRNAs in psoriasis patients undergoing risankizumab therapy, an anti-IL-23 monoclonal antibody, to understand its impact on disease pathogenesis and treatment response.
Trends in nanobody radiotheranostics.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave., Wuhan, Hubei, 430022, China.
As the smallest antibody fragment with specific binding affinity, nanobody-based nuclear medicine has demonstrated significant potential to revolutionize the field of precision medicine, supported by burgeoning preclinical investigations and accumulating clinical evidence. However, the visualization of nanobodies has also exposed their suboptimal biodistribution patterns, which has spurred collaborative efforts to refine their pharmacokinetic and pharmacodynamic profiles for improved therapeutic efficacy. In this review, we present clinical results that exemplify the benefits of nanobody-based molecular imaging in cancer diagnosis.
View Article and Find Full Text PDFFuture direction: molecular imaging-based stem cell research.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, 310009, China.
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable.
J Prev Alzheimers Dis
January 2025
Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
A 24-30 Centiloid (CL) threshold was collectively considered by a group of global dementia experts as a practical and implementable cut-off for anti-amyloid therapy intervention, in Alzheimer's disease patients who have been diagnosed at the mild cognitive impairment or mild dementia stage of their disease. Though additional validation is needed, knowledge of this threshold would be valuable to those involved in diagnosing and treating patients in the new AD care pathways, as well as entry into clinical trials. Therapy monitoring to determine future treatment response and assess amyloid clearance can be accomplished with amyloid PET with some technical details still to be elucidated.
View Article and Find Full Text PDFEditorial: Attacking Biological Problems Through Single-Molecule Approaches.
BMB Rep
January 2025
Department of Physics, Division of Interdisciplinary Bioscience & Bioengineering, POSTECH, Pohang 37673, Republic of Korea.
In the last few decades, single-molecule techniques have emerged as transformative tools for exploring biological problems. By observing and analyzing individual molecules, these methods make it possible to investigate fundamental dynamics of biomolecular processes deeper. Unlike traditional ensemble methods that average the behavior of populations, single-molecule approaches provide a unique window to observe molecular heterogeneity, transient interactions, and dynamic processes that are otherwise hidden.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!